News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
News New leader for UK’s molecular biology ‘Nobel Prize factory’ One of the UK’s leading institutes for early biomedical research has appointed Dr Jan Löwe as its new leader.
News AstraZeneca spies an upturn at last in 2018 AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.
News AZ boosted by COPD triple inhaler results AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.
News AZ's cancer and respiratory drugs approved in Japan Two AstraZeneca (AZ) drugs have been approved in Japan – its cancer drug Lynparza and its respiratory drug Fasenra.
News Regeneron: Biobank project offers hope for Alzheimer's R&D Regeneron R&D chief hopes UK data could find new Alzheimer's and Parkinson's drugs
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
